Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Czechia Greater than 99.8 % purity confirmed by COA Assay content verified at 22.6 mg Endotoxin level below 0.001 EU/mg No detectable heavy metals or microbial contamination High-purity peptide for controlled laboratory research For research use only not for human or veterinary use For laboratory research only
For Alzheimer disease, the current FDA-approved treatments include donepezil, rivastigmine, galantamine, memantine, and more recently lecanemab and donanemab (anti-amyloid antibodies with modest clinical effects)
My first plan for this topic had been to do a quick podcast on the data behind BPC-157, but there is literally nothing to talk about
What does 5 amino 1mq do for weight loss involves multiple mechanisms working synergistically
